Propiedad y actividad de insiders de Tarsus Pharmaceuticals, Inc. (TARS): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $77.64 |
| Capitalización | $3.3B |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-09-04 | Azamian Bobak R. | S-Sale | 7,100 | $641K |
| 2026-09-04 | Azamian Bobak R. | S-Sale | 2,900 | $265K |
| 2026-09-04 | Lin Elizabeth Yeu | S-Sale | 5,387 | $458K |
| 2026-09-04 | Lin Elizabeth Yeu | S-Sale | 1,590 | $135K |
| 2026-09-04 | Lin Elizabeth Yeu | S-Sale | 5,386 | $485K |
| 2026-09-04 | Lin Elizabeth Yeu | S-Sale | 1,590 | $143K |
| 2026-09-04 | Neervannan Seshadri | S-Sale | 4,564 | $388K |
| 2026-09-02 | Azamian Bobak R. | S-Sale | 10,000 | $801K |
| 2026-09-01 | Lin Elizabeth Yeu | S-Sale | 4,601 | $340K |
| 2026-09-02 | Lin Elizabeth Yeu | S-Sale | 5,387 | $431K |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $2.4M | $58.0M | $168.1M | $171.3M | $71.7M | $224.9M | $94.8M | $183.6M |
| Inversiones a Corto | 0 | 0 | 0 | $483000 | $145.4M | $2.5M | $196.6M | $233.6M |
| Cuentas por Cobrar | $4000 | $36000 | $20000 | $92000 | $3.6M | $17.7M | $48.1M | $87.1M |
| Inventario | 0 | 0 | 0 | 0 | 0 | $3.1M | $2.6M | $4.4M |
| Activos Corrientes | $2.4M | $58.0M | $170.7M | $176.0M | $225.4M | $256.1M | $356.7M | $522.8M |
| Inmovilizado Material | $6000 | $280000 | $1.2M | $1.8M | $1.5M | $3.3M | $2.9M | $21.7M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | $3.9M | $8.3M | $7.4M |
| Activos Totales | $2.4M | $58.3M | $172.0M | $178.9M | $227.9M | $265.5M | $377.0M | $562.2M |
| Cuentas por Pagar | $175000 | $456000 | $2.2M | $2.9M | $5.5M | $17.8M | $27.7M | $16.4M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $179000 | $819000 | $5.4M | $11.5M | $15.4M | $36.9M | $80.6M | $135.7M |
| Deuda a Largo | 0 | 0 | 0 | 0 | $19.4M | $29.8M | $71.8M | $83.0M |
| Pasivos Totales | $3.7M | $64.3M | $6.0M | $12.2M | $35.0M | $68.5M | $152.5M | $218.7M |
| Reservas | -$1.4M | -$6.0M | -$32.8M | -$46.7M | -$108.8M | -$244.7M | -$360.2M | -$426.6M |
| Patrimonio Neto | -$1.4M | -$6.0M | $166.0M | $166.7M | $192.9M | $197.0M | $224.5M | $343.4M |
| Deuda Total | 0 | $164000 | $831000 | $1.9M | $20.2M | $30.2M | $72.5M | $93.6M |
| Deuda Neta | -$2.4M | -$57.8M | -$167.3M | -$169.9M | -$196.8M | -$197.2M | -$218.9M | -$323.6M |
| Capital Circulante | $2.2M | $57.2M | $165.3M | $164.5M | $209.9M | $219.2M | $276.1M | $387.1M |
Salud financiera
| Deuda / Patrimonio | 0.27 |
| Ratio corriente | 3.85 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 9.54 |
Rentabilidad
| Rentabilidad sobre capital | -13.53% |
| Rentabilidad sobre capital invertido | -11.15% |
| Rentabilidad sobre activos | -7.60% |
| Margen bruto | 93.20% |
| Margen operativo | -15.72% |
| Margen neto | -14.72% |
Empresas relacionadas: AAPG · ADPT · ARQT · CELC · CGON · IRON · LEGN
Explorar sector: Healthcare · Biotechnology
Más secciones de TARS: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones